PatientsVille.com Logo


Pamidronate Medical Research Studies

Up-to-date List of Pamidronate Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Pamidronate Medical Research Studies

Rank Status Study
1 Recruiting The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Pamidronate;   Drug: Zoledronic acid;   Drug: placebo
Outcome Measures: sCTX values;   Palliative response
2 Recruiting Efficiency and Safety Study of Pamidronate in Inflammatory Back Pain Due to Degenerative Disk Disease
Conditions: Intervertebral Disc Degeneration;   Modic I Discopathy;   Back Pain;   Low Back Pain;   Magnetic Resonance Imaging (MRI)
Interventions: Drug: Pamidronate;   Other: Placebo
Outcome Measures: back pain assessed on a100mm VAS;   - Functional status using EIFEL, Dallas, FABQ, MacTar, and MCII/PASS questionnaires;   Back stiffness assessed by Schober's test and finger-to-floor distance;   Inflammatory pain pattern;   assess the efficacy of a rigid back brace in treating back pain;   Tolerance based on the number and types of side-effects
3 Not yet recruiting Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease
Conditions: Solid Tumor;   Metastatic Bone Disease
Interventions: Biological: denosumab;   Drug: Pamidronate
Outcome Measure: Total duration (in hours, minutes and seconds) for investigational product preparation and administration
4 Not yet recruiting Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation
Conditions: Osteopenia;   Osteoporosis
Interventions: Drug: Pamidronate;   Drug: Calcium and vitamin D
Outcome Measures: Lumbar spine bone mineral content;   Total body bone mineral content (TBMC; excluding head; adjusted for height, age, sex, Tanner stage, and race);   Total bone mineral density (BMD), cortical BMD, trabecular BMD, and estimated bone strength measured by pQCT;   Cytokine levels (interleukin IL-6, IL-7, and TNF-α);   Receptor activator of the nuclear factor-κB ligand [RANKL], osteoprotegerin [OPG], RANKL/OPG ratio;   Markers of bone resorption (carboxy-terminal collagen crosslinks [CTX] and deoxypyridinoline [DPD]);   Markers of bone formation (procollagen type 1 N-terminal propeptide [P1NP] and osteocalcin [OCN])
5 Unknown  Effect of Local Pamidronate in Preventing Bone Loss After Total Hip Arthroplasty
Conditions: Arthroplasty;   Mineral Density
Intervention: Drug: Pamidronate
Outcome Measures: Periprosthetic bone mineral density;   Biochemical markers of bone turnover
6 Unknown  Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer
Conditions: Chemotherapy;   Breast Cancer, Metastatic
Intervention: Drug: Cyclophosphamide, Capecitabine, Methotrexate, Celecoxib, Pamidronate (or Zoledronate)
Outcome Measures: To determine the efficacy by rate of clinical benefit (CB): rate of response (RR) + rate of Stable Disease (SD);   Plasma Levels of angiogenic growth factors
7 Recruiting Bisphosphonate Biomarker Study
Conditions: Osteoporosis, With or Without Treatment;   Bisphosphonate Treatment;   Atypical Femur Fracture;   Bisphosphonate Related Osteonecrosis of the Jaws (BRONJ);   Healthy Volunteers
Outcome Measures: Absorption, Distribution, Metabolism, Excretion (ADME) Profiling of DNA from all sample types vs. normative data for the ADME panel and across study groups;   Differential expression of miRNA biomarkers across participant groups within the study
8 Recruiting Study Into the Effect of Ibandronate for the Treatment of Bone Marrow Edema in Relation to Spontaneous or Non-traumatic Osteonecrosis of the Knee: A Randomized Double-blind, Placebo-controlled Trial
Conditions: Osteonecrosis of the Knee;   Bone Marrow Edema of the Knee
Interventions: Drug: Ibandronate IV;   Drug: Placebo
Outcome Measures: clinical outcome (pain [VAS score]);   radiological outcome (MRI knee);   number of salvage therapies needed in case persistence is observed during placebo therapy
9 Recruiting First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade
Condition: Multiple Myeloma
Interventions: Drug: VELCADE;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: DVT prophylaxis;   Drug: Bisphosphonates;   Drug: Liposomal doxorubicin
Outcome Measures: Number of patients with Minimal Residue Disease (MRD) negativity increase by twenty percent or greater;   Correlate MRD status;   Correlate MRD status between induction regimens
10 Recruiting European Phase III Study of APD421 in PONV
Condition: PONV
Interventions: Drug: APD421;   Drug: Placebo
Outcome Measure: Complete Response (protection from PONV)
11 Recruiting Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)
Condition: Viral Conjunctivitis
Interventions: Drug: APD-209 Eye drops;   Drug: APD-209 Placebo Eye drops
Outcome Measures: The primary objective is to assess the adenoviral load in epidemic keratokonjunctivitis (EKC) infected eyes following topical treatment with APD-209 Eye drops compared to placebo.;   Assess the time to viral eradication in EKC infected eyes following treatment with APD-209 Eye drops compared to placebo.;   Evaluate the effect of APD-209 Eye drops on clinical resolution of EKC, as measured by objective and subjective assessment of scaled clinical symptoms, compared to placebo.;   Evaluate the presence of opacities (quantitatively and qualitatively) following treatment with APD-209 Eye drops compared to placebo.;   Assess the visual acuity following treatment with APD-209 Eye drops compared to placebo.;   Assess the frequency of second eye infections.;   Assess the safety and tolerability of APD-209 Eye drops.
12 Recruiting US Phase III Study of APD421 in PONV
Condition: PONV
Interventions: Drug: APD421;   Drug: Placebo
Outcome Measure: Complete Response (protection from PONV)
13 Recruiting A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
Conditions: Cardiovascular Disease;   High Cardiovascular Risk;   Obesity;   Overweight;   Type 2 Diabetes
Interventions: Drug: APD356-Lorcaserin hydrochloride;   Drug: Placebo
Outcome Measures: Time from randomization to first occurrence of Major Adverse Cardiovascular Events (MACE);   Time from randomization to conversion to type 2 diabetes mellitus (T2DM) for subjects without any type of diabetes at Baseline;   Time from randomization to first occurrence of MACE+;   Time from randomization to event of each component of MACE+;   Time from randomization to event of all-cause mortality;   Time from randomization to event of new onset renal impairment or worsening existing renal impairment in subjects with T2DM at Baseline;   Time from randomization to event of improvement in renal function;   Change from Baseline in HbA[1c] at 6 months in subjects with T2DM at Baseline;   The proportion of subjects who meet FDA-defined valvulopathy in echocardiographically determined heart valve changes;   The percent change from Baseline in echocardiographically-determined pulmonary arterial systolic pressure;   Time to conversion to normal glucose homeostasis
14 Not yet recruiting Safety Study of APD-791 With Aspirin and/or Clopidogrel
Condition: Acute Coronary Syndrome
Interventions: Drug: Clopidogrel;   Drug: Aspirin;   Drug: APD791;   Drug: Placebo
Outcome Measures: To assess the safety of APD791 when orally co-administered with Aspirin and Clopidogrel in healthy subjects;   Pharmacokinetic characteristic evaluation variable;   Pharmacodynamic characteristic evaluation variable

These studies may lead to new treatments and are adding insight into Pamidronate etiology and treatment.

A major focus of Pamidronate research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Pamidronate